News Details
NCCN’s Annual Blood Cancer Program Shares Latest Advances in Care, Including Targeted Therapies, CAR-T Cell Recommendations and More
The NCCN 2024 Annual Congress: Hematologic Malignancies™ returns to New York City Friday, September 20 – Saturday, September 21. Virtual attendance is also available.
What: The National Comprehensive Cancer Network® (NCCN®) Annual Congress: Hematologic Malignancies™ is a certified continuing education event for the entire oncology team. Leaders in the field will present insights into the practical care of patients across a spectrum of hematologic malignancies, sharing the latest evidence and expert consensus-driven recommendations for improving outcomes for patients with blood cancers.
The meeting will highlight a debate on the new standard first-line therapy for Diffuse Large B-Cell Lymphoma and a review of oral targeted therapies in Acute Myeloid Leukemia (AML).
Other featured topics include:
- Challenges and Strategies for CAR T-Cell Therapies in Hematologic Malignancies
- Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Plus, updated treatment recommendations will be discussed for:
- Acute Lymphocytic Leukemia (ALL)
- Amyloidosis
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Chronic Myeloid Leukemia
- Follicular Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Myelofibrosis
- Primary CNS Lymphoma
When: September 20─21, 2024
Who: The faculty features hematology/oncology experts from across NCCN Member Institutions. The congress is chaired by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. Planning committee members include Gabriela S. Hobbs, MD, Mass General Cancer Center; Shaji K. Kumar, MD, Mayo Clinic Comprehensive Cancer Center; Bernard Marini, PharmD, BCOP, University of Michigan Rogel Cancer Center; and MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Visit NCCN.org/hem for the full agenda including all topics, faculty, and learning objectives.
Media can contact Rachel Darwin at darwin@nccn.org for complimentary press registration.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.